BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1993209)

  • 1. Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase.
    Baldwin SW; Tse A; Gossett LS; Taylor EC; Rosowsky A; Shih C; Moran RG
    Biochemistry; 1991 Feb; 30(7):1997-2006. PubMed ID: 1993209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase.
    Sanghani SP; Moran RG
    Biochemistry; 1997 Aug; 36(34):10506-16. PubMed ID: 9265631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis.
    Moran RG; Baldwin SW; Taylor EC; Shih C
    J Biol Chem; 1989 Dec; 264(35):21047-51. PubMed ID: 2592365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Side chain modified 5-deazafolate and 5-deazatetrahydrofolate analogues as mammalian folylpolyglutamate synthetase and glycinamide ribonucleotide formyltransferase inhibitors: synthesis and in vitro biological evaluation.
    Rosowsky A; Forsch RA; Reich VE; Freisheim JH; Moran RG
    J Med Chem; 1992 May; 35(9):1578-88. PubMed ID: 1578484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.
    Habeck LL; Mendelsohn LG; Shih C; Taylor EC; Colman PD; Gossett LS; Leitner TA; Schultz RM; Andis SL; Moran RG
    Mol Pharmacol; 1995 Aug; 48(2):326-33. PubMed ID: 7651366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and antifolate activity of 5-methyl-5,10-dideaza analogues of aminopterin and folic acid and an alternative synthesis of 5,10-dideazatetrahydrofolic acid, a potent inhibitor of glycinamide ribonucleotide formyltransferase.
    Piper JR; McCaleb GS; Montgomery JA; Kisliuk RL; Gaumont Y; Thorndike J; Sirotnak FM
    J Med Chem; 1988 Nov; 31(11):2164-9. PubMed ID: 3184124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol.
    Mendelsohn LG; Shih C; Schultz RM; Worzalla JF
    Invest New Drugs; 1996; 14(3):287-94. PubMed ID: 8958184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
    Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
    Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tetrahydrohomofolate polyglutamates as inhibitors of thymidylate synthase and glycinamide ribonucleotide formyltransferase in Lactobacillus casei.
    Thorndike J; Kisliuk RL; Gaumont Y; Piper JR; Nair MG
    Arch Biochem Biophys; 1990 Mar; 277(2):334-41. PubMed ID: 2106831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
    Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
    Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors.
    Habeck LL; Leitner TA; Shackelford KA; Gossett LS; Schultz RM; Andis SL; Shih C; Grindey GB; Mendelsohn LG
    Cancer Res; 1994 Feb; 54(4):1021-6. PubMed ID: 8313357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of glycinamide ribonucleotide formyltransferase and other folate enzymes by homofolate polyglutamates in human lymphoma and murine leukemia cell extracts.
    Thorndike J; Gaumont Y; Kisliuk RL; Sirotnak FM; Murthy BR; Nair MG; Piper JR
    Cancer Res; 1989 Jan; 49(1):158-63. PubMed ID: 2521177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel nonclassical inhibitors of glycinamide ribonucleotide formyltransferase: 10-formyl and 10-hydroxymethyl derivatives of 5,8,10-trideazapteroic acid.
    Liu L; Nair MG; Kisliuk RL
    J Mol Recognit; 1996; 9(2):169-74. PubMed ID: 8877810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
    Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP
    Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of HL-60 leukemia cell differentiation by tetrahydrofolate inhibitors of de novo purine nucleotide biosynthesis.
    Sokoloski JA; Beardsley GP; Sartorelli AC
    Cancer Chemother Pharmacol; 1991; 28(1):39-44. PubMed ID: 2040032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of HL-60 leukemia cell differentiation by the novel antifolate 5,10-dideazatetrahydrofolic acid.
    Sokoloski JA; Beardsley GP; Sartorelli AC
    Cancer Res; 1989 Sep; 49(17):4824-8. PubMed ID: 2758415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
    Smith SG; Lehman NL; Moran RG
    Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function.
    Bronder JL; Moran RG
    Cancer Res; 2002 Sep; 62(18):5236-41. PubMed ID: 12234990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The stereospecific cytotoxic potency of (6R) and (6S)-5,10- dideazatetrahydrofolate correlates with cellular folylpolyglutamate synthetase levels.
    Lehman NL
    Biochimie; 1995; 77(4):273-8. PubMed ID: 8589057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.